Department of Urology, Lanzhou University Second Hospital, 730000 Lanzhou, Gansu, China.
Institute of Urology, Lanzhou University Second Hospital, 730000 Lanzhou, Gansu, China.
Arch Esp Urol. 2024 Jan;77(1):79-91. doi: 10.56434/j.arch.esp.urol.20247701.11.
Given the growing recognition of molecular targets in oncology, this study aimed to examine the expression pattern and prognostic significance of human epidermal growth factor receptor-2 () in bladder cancer (BC) and the effects of knockdown on the biological behaviours of BC cells.
A total of 126 BC tissue samples and 20 samples of normal bladder mucosa were collected for immunohistochemical staining. The clinicopathological data were obtained from patients with BC. was knocked down in two BC cell lines (T24 and 5637) using lentiviral delivery of short hairpin RNA (shRNA), referred to as shHER2, with a blank control group (shCtrl) for comparison. A range of assays, including cell counting kit-8, colony formation, transwell, wound healing, and flow cytometry, were performed to assess the effects of knockdown on the proliferation, migration, cell cycle entry, and apoptosis of BC cells.
The study revealed a notable overexpression rate of in BC tissues (57.1%) than in normal bladder mucosa (0%) ( < 0.001). overexpression was associated with tumour number ( < 0.0001), pathological grade ( < 0.0001), lymph node metastasis ( = 0.040), distant metastasis ( = 0.037), overall survival ( = 0.0006), and recurrence-free survival (RFS) ( < 0.0001). In contrast, no significant association was identified between overexpression and demographic factors such as sex ( = 0.687), age ( = 0.430), tumour size ( = 0.053), or T stage ( = 0.134). Furthermore, the experimental knockdown of in BC cells inhibited the proliferation and migration and promoted their apoptosis and cell cycle arrest in the G1 phase.
The findings suggest as a potential therapeutic target for BC and underscore the promise of developing anti--targeting strategies for BC management.
鉴于人们对肿瘤学中分子靶标的认识不断提高，本研究旨在研究人类表皮生长因子受体-2（）在膀胱癌（BC）中的表达模式和预后意义，以及下调对 BC 细胞生物学行为的影响。
共收集 126 例 BC 组织样本和 20 例正常膀胱黏膜组织样本进行免疫组织化学染色。从 BC 患者中获得临床病理数据。使用慢病毒递送短发夹 RNA（shRNA）将两个 BC 细胞系（T24 和 5637）中的 敲低，并用空白对照组（shCtrl）进行比较。通过细胞计数试剂盒-8 测定、集落形成测定、Transwell 测定、划痕愈合测定和流式细胞术等一系列测定来评估 敲低对 BC 细胞增殖、迁移、细胞周期进入和细胞凋亡的影响。
研究表明，BC 组织中 过表达率（57.1%）明显高于正常膀胱黏膜（0%）（<0.001）。 过表达与肿瘤数量（<0.0001）、病理分级（<0.0001）、淋巴结转移（=0.040）、远处转移（=0.037）、总生存（=0.0006）和无复发生存（RFS）（<0.0001）有关。相比之下，在性别（=0.687）、年龄（=0.430）、肿瘤大小（=0.053）或 T 分期（=0.134）等人口统计学因素方面， 过表达与无显著相关性。此外，BC 细胞中 的实验下调抑制了增殖和迁移，促进了凋亡和 G1 期细胞周期阻滞。
这些发现表明 可能成为 BC 的潜在治疗靶点，并强调了开发针对 BC 管理的抗-靶向策略的前景。
